Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude d'oncologie de précision fondée sur la biopsie liquide pour évaluer l'utilité clinique du profilage génomique complet non invasif pour la sélection du traitement du cancer

Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Second, the investigators will investigate whether enacting upon MTB recommendations would improve outcomes in terms of progression-free and overall survival. Third, the investigators aim to determine if molecular profiling via serial plasma tests after initiation of chemotherapy or other targeted treatment is sufficient to determine whether or not a patient is responding to therapy.

Aperçu de l'étude

Description détaillée

  1. Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing.

    All information will be collected on study-specific case report forms (CRFs) hosted in Redcap and/or directly entered into a study database. The following measures will be taken to protect patient information:

    • The database will be password protected; only authorized staff may enter and view project data.
    • Passwords and system IDs will not be shared.
    • Physical security of the workstations/files will be maintained. Workstations with the database open will not be left unattended.
    • Staff will be trained on the data entry system and on security procedures.
    • The study data will be reviewed/monitored by the Sidney Kimmel Comprehensive Cancer Center Clinical Research Office and the Cancer Center Safety committee.
  2. Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.

    Data checks will be performed per SKCCC SOP DM-01-04 CRF Documentation Standards.

    Case Report Form (CRF): A printed, optical, or electronic document designed to record all of the protocol-required information to be reported to the sponsor on each trial subject. ICH GCP 1.11 Source Documents: Original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at the medicotechnical departments involved in the clinical trial). ICH GCP 1.52

  3. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (for example, medical records, paper or electronic case report forms, or interactive voice response systems).

    All study data will be reviewed for completeness and accuracy by the Protocol Chair who will ensure the completeness and accuracy of the data generated. The designated research coordinator(s) participating in this project will collect clinical information associated with each participant. Such data could include, but is not limited to: medical record number, age, sex, treatment history, circulating tumor markers, tumor size, tumor grade, tumor receptor status, pathology report, smoking history, hormonal history, concomitant medications, and parity. Such information will be retrieved from existing clinical databases/EMR (e.g., EPIC) and patient questionnaire information, and may also include electronic scheduling and prescription systems.

    Follow-up information will be collected by review of the medical records. In addition, participants may be reached by phone to help with any questions or clarifications, or additional follow-up requirements.

  4. Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information if used (for example, World Health Organization Drug Dictionary, MedDRA), and normal ranges if relevant.

    Source for data dictionary is included in Botsis et al., JCO CCI, 2023, in press.

  5. Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.

    These activities will be carried out in compliance with the study protocol and Good Clinical Practice principles. Information regarding study conduct and progress will be reported to our local Institutional Review Board (IRB) per current institutional standards. The study will undergo routine annual review as per current institutional standards.

  6. Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect.

    We will recruit 150 patients with solid tumors including non-adenocarcinoma NSCLC, small-cell lung cancer, neuroendocrine lung cancer, mesothelioma, esophageal cancer, breast cancer and head and neck cancer. Based on the liquid biopsy assay's analytical performance we expect to detect tumor-specific mutations in >85% of the individuals. We expect to complete the accrual in 1.5 years. The analysis is primarily descriptive for this feasibility study. A sample size of 150 patients will provide reasonable confidence around the observed estimate of proportions, e.g. percent of patients with variants of clinical significance. The width of 95% confidence interval will be narrower than 16.5%.

  7. Plan for missing data to address situations where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.

    Missing data will be excluded from downstream analyses.

  8. Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.

    1. Analysis of Primary Objectives:

      The primary objectives are to determine the number and prevalence of variants with clinical significance across different levels of evidence (stratified by gene and alteration type), as described above and to determine the percentage of patients with an MTB treatment recommendation accordingly. Descriptive analysis will be performed to estimate the percentage of patients that harbor variants with clinical significance detected in ctDNA samples, along with 95% confidence intervals. The percentage of patients with an MTB treatment recommendation tailored to an actionable alteration according to the mutation profiles detected by liquid biopsies, and percentage of patients treated according to MTB recommendation will be estimated. The days from collection of liquid biopsies to MTB recommendation, and days from MTB recommendation to treatment initiation will be summarized by mean, median, standard deviation and range. We plan to summarize the data after every 30 patients.

    2. Analysis of Secondary Objectives:

Time to subsequent cancer therapy is the time from initiation of treatment to the start of next cancer therapy according to treating physician's decision. Progression-free survival (PFS) is the time from initiation of therapy to radiographic progression per RECIST, clinical progression or worsening disease per treating physician's assessment. Overall survival (OS) is the time from initiation of therapy to death due to any cause. PFS and OS will be characteristics by Kaplan-Meier method, among patients who do and do not have an MTB recommendation, and for patients who do and do not receive recommended treatment.

Descriptive analysis will be performed to report the frequency of MTB-based treatment recommendations by therapeutic class (standard of care, clinical trial, off-label use), and the deviations from treatment recommendations and reasons (clinical deterioration, other protocol, patient ineligible, off-label treatment unavailable, clinical trial not feasible (e.g. physical distance), clinical trial not recruiting, physician's decision, patient's choice, etc.) The concordance of detected alterations obtained through liquid biopsy analyses at baseline compared to time-matched or archival tissue specimens will be summarized and quantified using Kappa statistics.

Descriptive analyses will also be performed to determine the cell-free DNA yield and ctDNA amount by tumor type obtained through liquid biopsy analyses. Additionally, the assay success rate by tumor type and by pre-analytical variables will be performed across minimum technical data elements, including:

  • Blood collection tube type
  • Sample composition
  • Shipping temperature
  • Blood fractionalization method
  • Time to fractionation
  • Analyte isolation method
  • Time to freezer
  • Storage temperature
  • Concentration: cellular concentration or molecular concentration
  • Assay method
  • Time to assay

Type d'étude

Observationnel

Inscription (Estimé)

200

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Maryland
      • Baltimore, Maryland, États-Unis, 21287
        • Recrutement
        • Johns Hopkins University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

N/A

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Patients with solid tumors, including esophageal cancer, non-adenocarcinoma NSCLC, small-cell lung cancer, head & neck cancer, mesothelioma, breast cancer and lung neuroendocrine cancer.

La description

Inclusion Criteria:

  • ECOG performance status of 0-1.
  • Patients with solid tumors, including esophageal cancer, non-adenocarcinoma NSCLC, small-cell lung cancer, head & neck cancer, mesothelioma, breast cancer and lung neuroendocrine cancer.
  • Patients who can provide whole blood collection to meet minimum of 20-30ml of blood at baseline, within 1-3 weeks from treatment initiation, at first radiographic imaging and at progression. Acquisition of an archival or time-matched tumor tissue specimen which meets the minimum sample input requirements (at least 20% tumor content and 100 ng) is preferred but not required.
  • Patients with metastatic disease will have progressed on the most recent treatment prior to enrollment. Patient can also be enrolled if their oncologist believes progression is imminent and test results would be used to inform next line of therapy. Patients considered for first-line SOC therapeutic options may be enrolled if the clinical efficacy of these therapies is not encouraging.
  • Patients must have disease evaluable for progression assessment; measurable disease is not required to participate in the study.
  • Able to voluntarily provide informed consent.

Exclusion Criteria:

  • Women who are known to be pregnant
  • History of another primary malignancy in the last 5 years prior to registration unless approved by the Protocol Chair/designee. Patients with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: OTHER
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Oncology Patients

All participants in the study.

Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Prevalence of variants in ctDNA with clinical significance across different levels of evidence
Délai: Up to 2 years after enrollment

To determine the prevalence of variants in ctDNA with clinical significance across different levels of evidence (stratified by gene and alteration type). In cases where tumor next-generation sequencing has been performed, tumor mutational profiles will be evaluated in conjunction with the liquid biopsy results.

Up to 2 years after enrollment
Percentage of patients with a molecular tumor board (MTB) treatment recommendation
Délai: Up to 2 years after enrollment

To determine the percentage of patients with a molecular tumor board (MTB) treatment recommendation tailored to an actionable alteration according to the mutation profiles detected by liquid biopsies.

Up to 2 years after enrollment
Percentage of patients treated according to MTB recommendation
Délai: Up to 2 years after enrollment

To determine percentage of patients treated according to MTB recommendation.

Up to 2 years after enrollment
Turnaround time from collection of liquid biopsy to MTB recommendation
Délai: Up to 2 years after enrollment

To determine turnaround time from collection of liquid biopsy to MTB recommendation.

Up to 2 years after enrollment
Time from MTB recommendation to treatment initiation
Délai: Up to 2 years after enrollment

To determine the time from MTB recommendation to treatment initiation.

Up to 2 years after enrollment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Time to cancer therapy for patients who are treated according to MTB recommendation
Délai: Up to 2 years after enrollment

To determine time to subsequent cancer therapy for patients who are treated according to MTB recommendation.

Up to 2 years after enrollment
Time to cancer therapy for patients who are not treated according to MTB recommendation
Délai: Up to 2 years after enrollment

To determine time to subsequent cancer therapy for patients who are not treated according to MTB recommendation.

Up to 2 years after enrollment
Progression free-survival of patients who are treated according to the MTB recommendations
Délai: Up to 2 years after enrollment

To determine the progression free-survival of patients who are treated according to the MTB recommendations.

Up to 2 years after enrollment
Progression free-survival of patients who are not treated according to the MTB recommendations
Délai: Up to 2 years after enrollment

To determine the progression free-survival of patients who are not treated according to the MTB recommendations.

Up to 2 years after enrollment
Overall survival of patients who do receive treatment according to the MTB recommendations
Délai: Up to 2 years after enrollment

To determine the overall survival of patients who do receive treatment according to the MTB recommendations.

Up to 2 years after enrollment
Overall survival of patients who do not receive treatment according to the MTB recommendations
Délai: Up to 2 years after enrollment

To determine the overall survival of patients who do not receive treatment according to the MTB recommendations.

Up to 2 years after enrollment
MTB-based treatment recommendations stratified by therapeutic class
Délai: Up to 2 years after enrollment

To determine MTB-based treatment recommendations stratified by therapeutic class (SOC, clinical trials, off-label use).

Up to 2 years after enrollment
Proportion of deviations from treatment recommendations
Délai: Up to 2 years after enrollment

To determine the proportion of deviations from treatment recommendations.

Up to 2 years after enrollment
Reasons for deviations from treatment recommendations
Délai: Up to 2 years after enrollment

To determine the reasons (clinical deterioration, other protocol, patient ineligible, off-label treatment unavailable, clinical trial not feasible (e.g. physical distance), clinical trial not recruiting, physician's decision, patient's choice, etc.) for deviations from treatment recommendations.

Up to 2 years after enrollment
Concordance of detected alterations obtained through liquid biopsy analyses
Délai: Up to 2 years after enrollment

To determine the concordance of detected alterations obtained through liquid biopsy analyses at baseline compared to next generation sequencing of time-matched or archival tissue specimens.

Up to 2 years after enrollment
cfDNA yield obtained
Délai: Up to 2 years after enrollment

To determine the cfDNA yield obtained through liquid biopsy analyses by tumor type.

Up to 2 years after enrollment
ctDNA amount obtained
Délai: Up to 2 years after enrollment

To determine the ctDNA amount obtained through liquid biopsy analyses by tumor type.

Up to 2 years after enrollment
Liquid biopsy assay success rate
Délai: Up to 2 years after enrollment

To determine the liquid biopsy assay success rate by tumor type and by pre-specified pre-analytical variables.

Up to 2 years after enrollment

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Correlation of changes in ctDNA levels with radiologic response
Délai: Up to 2 years after enrollment

To determine the correlation of changes in ctDNA levels with radiologic response by RECIST.

Up to 2 years after enrollment
Correlation of changes in ctDNA levels to progression-free survival
Délai: Up to 2 years after enrollment

To determine the correlation of changes in ctDNA levels to progression-free survival.

Up to 2 years after enrollment
Correlation of changes in ctDNA levels to overall survival
Délai: Up to 2 years after enrollment

To determine the correlation of changes in ctDNA levels to overall survival.

Up to 2 years after enrollment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Valsamo Anagnostou, MD, PhD, Johns Hopkins University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 janvier 2023

Achèvement primaire (Estimé)

1 septembre 2027

Achèvement de l'étude (Estimé)

1 septembre 2027

Dates d'inscription aux études

Première soumission

14 octobre 2022

Première soumission répondant aux critères de contrôle qualité

14 octobre 2022

Première publication (Réel)

19 octobre 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • J2271
  • IRB00333925 (Autre identifiant: Johns Hopkins IRB)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner